GLP-1 Lab Tests: What's Out There
Understanding the lab tests available for GLP-1 monitoring — from standard blood panels to advanced transcriptomic analysis. Whether you're on Ozempic, Wegovy, Mounjaro, or Zepbound, here's what each approach reveals about your therapy response.
Two Approaches to GLP-1 Monitoring
There are two fundamentally different ways to monitor your GLP-1 therapy — each revealing different information about your health.
Approach 1
Standard Lab Testing
The foundation of GLP-1 monitoring — available through any clinical laboratory such as Labcorp, Quest, or your provider's in-office lab. Includes metabolic panels, lipids, thyroid function, HbA1c, insulin, CBC, and inflammatory markers.
- 7 panel categories
- 30+ individual analytes
- Lagging indicators (what already happened)
Approach 2
Transcriptomic Testing
What Biomeme Labs offers beyond standard labs. Whole-blood mRNA gene expression profiling that reveals what your immune cells are transcribing right now — mapping 3 Health Domains (Activation, Antiviral Response, and Resolution) with cellular deconvolution. Real-time molecular intelligence.
- Whole-blood transcriptomic profiling
- 4-node longitudinal test series
- Dynamic immune programs (Activation, Antiviral, Resolution)
Biomeme Labs does not offer standard blood panels.
We specialize in molecular-level transcriptomic testing that reveals what standard labs cannot.
Standard GLP-1 Lab Tests
These are the standard blood tests commonly ordered for GLP-1 therapy monitoring. They provide valuable clinical data about your metabolic health. Your prescribing provider may order these through any clinical laboratory.
Comprehensive Metabolic Panel (CMP)
14 analytes
What it measures
Liver function (ALT, AST, alkaline phosphatase, bilirubin), kidney function (creatinine, BUN, eGFR), electrolytes (sodium, potassium, chloride, CO2), blood sugar (glucose), and protein levels (albumin, total protein).
Why it matters on GLP-1 therapy
Rapid weight loss mobilizes fat stored in the liver, which can temporarily stress hepatic function. GLP-1 medications also affect how your kidneys process waste products. The CMP is your safety baseline — catching liver enzyme elevations, kidney strain, or electrolyte imbalances early, before they become clinical problems.
What to watch for
Rising ALT/AST (liver stress during fat mobilization), declining eGFR (kidney function), and electrolyte shifts — especially potassium — during periods of reduced food intake or GI side effects.
Lipid Panel
4 analytes
What it measures
Total cholesterol, LDL ("bad") cholesterol, HDL ("good") cholesterol, and triglycerides — the complete cardiovascular lipid picture.
Why it matters on GLP-1 therapy
GLP-1 medications have demonstrated significant cardiovascular benefits in landmark clinical trials (SELECT, SURPASS). Triglycerides often drop within the first 4–8 weeks — making them one of the earliest traditional indicators of downstream metabolic shifts. LDL and HDL improvements typically follow over months.
What to watch for
Falling triglycerides (early positive signal), improving LDL/HDL ratio, and total cholesterol trends. Persistently elevated triglycerides provide clinical context for you and your prescriber to evaluate.
Thyroid Panel
TSH + Free T4
What it measures
TSH (thyroid-stimulating hormone) tells you how hard your pituitary gland is pushing your thyroid to work. Free T4 measures the actual thyroid hormone available to your body. Together, they give a complete picture of thyroid function.
Why it matters on GLP-1 therapy
All GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, and Zepbound — carry an FDA boxed warning regarding medullary thyroid carcinoma (MTC), based on findings in rodent studies. While human risk remains low, thyroid monitoring is standard clinical practice during GLP-1 therapy, especially for individuals with a personal or family history of thyroid conditions.
What to watch for
Significant TSH changes, new thyroid nodules or neck swelling, and any shift in Free T4 that could indicate hypo- or hyperthyroidism developing during therapy.
HbA1c (Glycated Hemoglobin)
Normal: <5.7%
What it measures
Your average blood sugar over the past 2–3 months — the gold standard for long-term glycemic control. Unlike a single fasting glucose reading, HbA1c shows the sustained trend.
Why it matters on GLP-1 therapy
Whether you're taking GLP-1s for diabetes management or weight loss, HbA1c is your most reliable progress marker. A baseline reading gives your provider a starting point; subsequent tests confirm whether the medication is producing sustained improvements — not just daily fluctuations.
What to watch for
Steady decline from baseline indicates favorable glycemic trends. A plateau or secondary rise provides objective context for reviewing your lifestyle and therapeutic protocol with your doctor.
Fasting Insulin
Normal: 2.6–24.9 µIU/mL
What it measures
How much insulin your pancreas is producing after an overnight fast. This is a direct measure of insulin resistance — the core metabolic dysfunction that GLP-1 medications target.
Why it matters on GLP-1 therapy
Falling fasting insulin means your body needs less insulin to control blood sugar — a sign your insulin sensitivity is improving. GLP-1 medications like Ozempic and Mounjaro should steadily drive this number down. If fasting insulin remains persistently elevated, your provider may need to reassess your treatment plan.
What to watch for
Progressive decline indicates improving insulin sensitivity. Persistently high levels provide objective data for your healthcare provider to consider when reviewing your overall therapeutic protocol.
Complete Blood Count (CBC)
Full differential
What it measures
Red blood cells, white blood cells, platelets, hemoglobin, and hematocrit — a comprehensive view of your overall health, immune function, oxygen-carrying capacity, and clotting ability.
Why it matters on GLP-1 therapy
Caloric restriction and rapid weight loss — common during GLP-1 therapy — can affect blood cell production. A CBC catches anemia (from nutritional deficiencies), immune changes, and general health shifts that could indicate your body isn't tolerating the metabolic transition well.
What to watch for
Declining hemoglobin or red cell counts (possible nutritional anemia), elevated white cells (infection or inflammation), and platelet changes that could signal systemic stress.
Inflammatory Markers — hs-CRP
Low risk: <1.0 mg/L
What it measures
High-sensitivity C-reactive protein (hs-CRP) measures systemic inflammation levels — a key driver of metabolic disease, cardiovascular risk, and chronic health conditions.
Why it matters on GLP-1 therapy
GLP-1 medications have demonstrated remarkable anti-inflammatory properties beyond weight loss. A falling hs-CRP confirms these benefits are active for you — not just theoretical. Tracking acute-phase markers provides essential clinical context on hepatic inflammatory signaling during GLP-1 therapy.
What to watch for
Declining hs-CRP is a strong positive signal. Persistently elevated levels may indicate the anti-inflammatory benefits aren't engaging — and this is where molecular-level testing can add critical context.
What Biomeme Labs Offers Beyond Standard Labs
While standard labs tell you what has already changed, Biomeme Labs reveals what is actively changing at the molecular level. Our mRNA transcriptomic profiling goes beyond traditional blood work to provide real-time molecular intelligence about your GLP-1 therapy.
Innate Sensing & Mobilization
7 pathways capturing danger sensing, inflammatory cytokine cascades, myeloid effectors, and vascular containment.
- Innate Sensing & TLRs — Primary pattern-recognition activation
- Neutrophils & Monocytes — First-responder myeloid effector programs
- Platelet Containment — Thrombo-inflammatory vascular load
Antiviral Response
1 grouped pathway spanning 4 antiviral modules (S1–S4) monitoring the Type I interferon defense system.
- Type I Interferon — Core viral defense gene cascades
- Antiviral S1–S4 Modules — Multi-tiered cellular defense signatures
- Sterile vs. Viral Signals — Distinguishing therapy from infections
Active Resolution & Clean
2 pathways governing active immune stand-down machinery, negative feedback, and tissue clearance.
- Stop & Stand Down — Checkpoint inhibitors and braking mechanisms
- Tissue Clearance — Cellular clean-up and damage resolution
- Resolution Deficit — Catching whether inflammation fails to finish
Cellular Deconvolution
The census plus the orders: separating changes in cell counts from changes in cellular activation states.
- Leukocyte Subsets — Algorithmic quantification of immune cell fractions
- Cell-State Dissection — Distinguishes more cells from more active cells
- Independent Signals — No composite score hiding vital details
How It Works
Our testing uses whole-blood mRNA transcriptomic profiling, delivered as a 4-node longitudinal test series across your GLP-1 therapy. A mobile phlebotomist comes to you — available across 42 states, no office visits required. Results are delivered to your personal dashboard within ~1 month. All testing is performed in our CLIA-certified laboratory.
The Transcriptomic Difference
Standard labs show you the scoreboard. Transcriptomic testing shows you the biological programs in progress. Labcorp, Quest, and other major labs offer excellent standard blood chemistry. But they measure single proteins and end products with hours-to-weeks of lag. Biomeme Labs' Inflammation Compass™ reads circulating immune cells to evaluate whether innate activation pathways are cooling, whether active resolution has engaged, and how leukocyte states are shifting — providing a biological window throughout GLP-1 titration, maintenance, and tapering.
The 4-Node Testing Schedule
Biomeme Labs' transcriptomic testing is structured as a 4-node series, designed to track your molecular response across the key stages of GLP-1 therapy.
Baseline
Day 0 starting baseline — establishes your personal 3-domain immune baseline and leukocyte census, whether drawn before your first dose or upon entering monitoring while on therapy.
1 Month
Week 4 early kinetics — captures early systemic inflammatory calming, which clinical trials show begins weeks before significant weight loss.
3 Months
Week 12 adaptation — tracks consolidated metabolic calming and active resolution signaling, especially valuable during weight-loss plateaus.
Maintenance & Off-Ramp
Month 12+ & Discontinuation — surveillance for cellular inflammatory recurrence. Over 65% discontinue within a year; evaluates whether systemic calming holds as adipose epigenetic memory challenges maintenance or tapering.
Common Questions About
GLP-1 Lab Testing
What standard blood tests are used for GLP-1 monitoring?
Standard GLP-1 monitoring typically includes seven categories of blood work — a Comprehensive Metabolic Panel (CMP) covering liver function, kidney function, electrolytes, and glucose; a complete Lipid Panel (total cholesterol, LDL, HDL, triglycerides); a Thyroid Panel (TSH and Free T4); HbA1c for 3-month glucose averaging; Fasting Insulin for insulin resistance assessment; a Complete Blood Count (CBC) with differential; and hs-CRP for systemic inflammation. These tests are available through any clinical laboratory and are typically ordered by your prescribing provider.
What does Biomeme Labs offer?
Biomeme Labs specializes in whole-blood transcriptomic testing — not standard blood chemistry. Our test, the Inflammation Compass™, uses RNA sequencing and cellular deconvolution to measure what your circulating white blood cells are actively transcribing. Rather than looking at a single downstream liver protein or simple cell counts, the Compass maps 3 Health Domains: Activation, Antiviral Response, and Resolution. All testing is performed in our CLIA-certified laboratory, with mobile phlebotomy across 42 states and results delivered to your personal dashboard within ~1 month.
How is this different from a standard Labcorp or Quest panel?
Labcorp, Quest, and other major labs offer excellent standard blood work — which your provider should continue to order. Biomeme Labs does not duplicate that testing. Instead, we provide the whole-blood transcriptomic layer that standard labs cannot offer. Standard labs measure static endpoint proteins like hs-CRP (a single liver protein with hours-to-weeks of lag) and cell headcounts (CBC), but they cannot tell you which inflammatory programs are active or whether active biological resolution has engaged. The Inflammation Compass™ provides a biological window into systemic inflammatory calming throughout GLP-1 titration, maintenance, and tapering.
How do I order and what's the process?
You can order Biomeme Labs' transcriptomic testing directly online through our order page. Once ordered, a mobile phlebotomist comes to you — no office visits required. Your blood sample is sent to our CLIA-certified laboratory for analysis, and results are delivered to your personal dashboard within ~1 month. Direct-access ordering is currently available in 42 states. Individuals in states with direct-access restrictions (CA, CT, MA, MD, NJ, NY, PA, RI) may contact us as we work to expand coverage.
Dive Deeper Into
GLP-1 Monitoring
Biomarker Deep-Dive
Explore every biomarker in detail — what it measures, why it matters, and what your results mean.
View biomarkersThe mRNA Layer
How gene expression monitoring works, what it adds to standard blood work, and why it matters for GLP-1 members.
Learn moreTesting Schedule
The full 4-node testing schedule — when to test and what each node reveals about your therapy response.
View schedule See What Transcriptomic
Testing Reveals
Go beyond standard blood work. Starting at $600 for your 2-node baseline package, with optional continuous monitoring at $250 per node. Mobile phlebotomy across 42 states included.